Antares Pharma's Licensee Announces First Transdermal Estradiol Gel With Three Doses That Significantly Decrease Hot Flashes in

88% Decrease in Hot Flashes and the Lowest Effective Dose is Established, According to the Results Reported 


EXTON, Pa., Sept. 30  /PRNewswire-FirstCall/ -- Antares Pharma, Inc. (AMEX:AIS) announced today that its North American licensee, BioSante Pharmaceuticals, Inc. (AMEX:BPA) has presented a full report of the results of its Phase III clinical study data on Bio-E-Gel(TM) (bio-identical estradiol gel) at the North American Menopause Society (NAMS) annual meeting in San Diego, CA.  The study results showed three doses of Bio-E-Gel(TM) that significantly decrease the number of hot flashes in menopausal women and identified the lowest effective dose in order to implement estrogen therapy.

The Phase III trial was a 12-week, randomized, double-blind, placebo- controlled study of 484 symptomatic menopausal women using three dosage levels of Bio-E-Gel(TM) in order to establish safety and efficacy of Bio-E-Gel(TM) for the treatment of hot flashes, which are known to occur in up to 85% of menopausal women.  Results showed that the most effective dose decreased the number of hot flashes by 88% from 12.9 per day at baseline to 1.6 after treatment (p